Thérapies moléculaires ciblées dans le cancer du poumon à petites cellules

摘要: Small-cell lung cancers (SCLC) are aggressive malignancies, however, characterized by high primary chemosensitivity. Unfortunately, for the vast majority of patients, relapse is rule with emergence secondary resistance mechanisms. In era molecular targeted therapies, characterization a number abnormalities has encouraged implementation several clinical trials. This literature review summarizes various pharmacological approaches used in SCLC to improve survival localized and extensive forms disease. Initial trials therapies have not been able outcome compared standard etoposide-cisplatin chemotherapy regimen forms. However, new targets continue be identified many treatments currently being assessed, including blockade angiogenesis, signal transduction, cell cycle or induction apoptosis.